Kintegral Advisory LLC Sells 188 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Kintegral Advisory LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,046 shares of the medical research company’s stock after selling 188 shares during the quarter. Kintegral Advisory LLC’s holdings in IQVIA were worth $795,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of IQV. Capital Performance Advisors LLP bought a new position in IQVIA during the third quarter valued at $27,000. Synergy Asset Management LLC purchased a new stake in shares of IQVIA during the 4th quarter valued at about $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Assetmark Inc. increased its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the last quarter. Finally, Concord Wealth Partners purchased a new stake in IQVIA during the third quarter valued at approximately $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Down 1.6 %

NYSE IQV opened at $190.94 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $33.62 billion, a price-to-earnings ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The company’s 50-day simple moving average is $199.57 and its two-hundred day simple moving average is $216.34. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Finally, Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.